When used in experimental animal models of CKD, phosphate binder reduced serum FGF-23 levels (Ghorbanihaghjo et al., 2018) with a significant reduction in aortic calcification (Finch et al., 2013; Wu-Wong et al., 2016). This evidence concerns the gene FGF23 and chronic kidney disease.